

Mirtazapine-induced akathisia

Boregowda G Girishchandra,*
Liana Johnson,[†] Rebecca M Cresp,[‡]
Kenneth G D Orr[§]

* Registrar in Psychiatry, [†]Senior Pharmacist, [‡]Intern in Psychiatry, [§]Psychiatrist, Fremantle Hospital, Fremantle, WA 6160. kenneth.orr@health.wa.gov.au

TO THE EDITOR: Akathisia is a clinical syndrome that manifests as the subjective sense of unease or restlessness, or observable motor manifestations such as shuffling or tramping movements of the legs and feet, or both.¹ The marked distress associated with akathisia can lead to impulsive suicide attempts.² It is commonly associated with antipsychotic medications, as well as various antidepressants, including tricyclics and selective serotonin reuptake inhibitors (SSRIs).

Mirtazapine is a novel antidepressant. It acts centrally to increase both noradrenergic and serotonergic neurotransmission. Common side effects include sedation, weight gain and increased appetite. Tremor is listed as an adverse reaction, but this does not represent akathisia. A MEDLINE database search (up to September 2001), using the words "akathisia" and "mirtazapine", did not reveal any reports of an association. However, as of mid-November 2001, the Adverse Drug Reactions Advisory Committee (ADRAC) had received five reports of "hyperkinesia (probably equivalent to akathisia)" associated with mirtazapine.

We would like to report two cases of acute akathisia associated with mirtazapine.

A 52-year-old man was referred by his psychiatrist for inpatient management of his depressive illness. He had previously tried multiple antidepressants, including various tricyclics and SSRIs. However, because of the sexual side effect anorgasmia, adherence to antidepressant treatment was poor. He was prescribed mirtazapine (30 mg at night). Within an hour of taking the first dose, he complained of feeling restless and unable to keep his legs still. He was given 1 mg of clonazepam, which settled his symptoms after 30 minutes. He was also observed to jiggle his legs and feet while at rest. His symptoms recurred the next day, necessitating further successful treatment with clonazepam. Mirtazapine therapy was continued, and the patient's depression improved significantly over the next few days, and the akathisia gradually resolved with regular use of clonazepam.

A 73-year-old woman with chronic depression was admitted after an overdose. Her medications on admission were omeprazole, amiodarone, bendrofluzide and fluvoxamine (50 mg). The fluvoxamine was

changed to mirtazapine (15 mg/day initially, increased to 30 mg/day after three days). After the first 30 mg dose, she described intense restlessness in her legs lasting up to two hours. The distress necessitated reintroducing the fluvoxamine in place of the mirtazapine. Within three weeks the patient was readmitted with depressed mood and suicidal ideation. Mirtazapine (30 mg at night) was reintroduced, with consequent acute return of restless legs. The patient's akathisia settled when the mirtazapine was reduced to 15 mg at night. No additional treatment was required.

The neurobiological basis for akathisia remains unclear. Involvement of central serotonergic and adrenergic neurotransmitter systems has been postulated. One of mirtazapine's main actions is blockade of α_2 -adrenoreceptors. Clonidine, an α_2 -agonist, is effective in treating akathisia.³ We suggest that mirtazapine's adrenoceptor action might be the basis for the occurrence of akathisia in these patients.

1. Sachdev P, Loneragan C. The present status of akathisia. *J Nerv Ment Dis* 1991; 179: 381-392.
2. Drake RE, Erlich J. Suicide attempts associated with akathisia. *Am J Psychiatry* 1985; 142: 499-501.
3. Zubenko GS, Cohen BM, Lipinski JF Jr, Jonas JM. Use of clonidine in treating neuroleptic-induced akathisia. *Psych Res* 1984; 13: 253-259. □

Vitamin D deficiency and multicultural Australia

Paul Glendenning

Registrar, Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, WA 6000 paul.glendenning@health.wa.gov.au

TO THE EDITOR: In a recent editorial, Mason and Diamond state that ergocalciferol (vitamin D₂) is bioequivalent to cholecalciferol (vitamin D₃) and that 1000 IU/day of ergocalciferol is sufficient for the treatment of vitamin D deficiency.¹ Both statements are contentious. Although ergocalciferol (vitamin D₂) is the only single prohormonal form of vitamin D available on prescription in Australia, there are three reasons to be cautious about the use and dose equivalence of ergocalciferol (vitamin D₂) compared with cholecalciferol (vitamin D₃).

Cholecalciferol (and not ergocalciferol) has been shown in two randomised trials to reduce fracture rates when administered concomitantly with calcium to elderly patients.^{2,3} Furthermore, all recently studied agents for treating postmenopausal osteoporosis (alendronate, risedronate, raloxifene and parathyroid hormone 1-34 [the first 34 amino acids of the hormone])

were shown to lower fracture rates, but study participants were routinely given supplementary calcium and vitamin D when deficiency was established. At least two studies specified the use of cholecalciferol.

Vitamin D₂ (ergocalciferol) and vitamin D₃ (cholecalciferol) are probably not bioequivalent.^{4,5} Ergocalciferol administration to vitamin-D-replete premenopausal women reduced the amount of circulating 25-hydroxyvitamin D₃ (25OHD₃) while only modestly increasing 25OHD₂ levels, with a resultant marginal effect on the total 25OHD level.⁴ In contrast, the equivalent dose of cholecalciferol increased the circulating level of 25OHD₃ significantly.⁴

Lastly, while radioimmunoassays (RIAs), such as the INCSTAR/DioSorin assay (Stillwater, Minnesota, USA), used in both studies of vitamin D levels published recently in the *MJA*^{6,7} are able to measure 25OHD levels, they are incapable of differentiating between 25OHD₂ and 25OHD₃. Furthermore, neither of the commercially available RIAs (the other one is made by IDS Ltd, Tyne and Wear, UK) is able to measure both vitamin D metabolites with equivalent accuracy. In a study comparing RIAs for the measurement of 25OHD against high performance liquid chromatography (the gold standard method) both assays did not recognise 25OHD₂ as well as 25OHD₃, with r^2 of 0.74 and 0.58, respectively, for 25OHD₂.⁸ Until further research is available, using more patients and a greater number with vitamin D deficiency, caution must be exercised in the interpretation of 25OHD levels measured with RIAs. This applies especially to individuals taking ergocalciferol (vitamin D₂) for the treatment of vitamin D deficiency.

Thus, it would appear that cholecalciferol (vitamin D₃) has a role to play in the reduction of osteoporotic fractures, but only when administered with calcium. If administering ergocalciferol (vitamin D₂), a far greater dose than 1000 IU/day may be needed, and the use of commercial RIAs to determine the therapeutic response may be misleading.

Competing interests: None declared.

1. Mason RS, Diamond TH. Vitamin D deficiency and multicultural Australia [editorial]. *Med J Aust* 2001; 175: 236-237.
2. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D₃ and calcium to prevent hip fractures in elderly women. *N Engl J Med* 1992; 327: 1637-1642.
3. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997; 337: 670-676.
4. Tjellesen L, Hummer L, Christiansen C, Rodbro P. Serum concentration of vitamin D metabolites during treatment with vitamin D₂ and D₃ in normal premenopausal women. *Bone Miner* 1986; 1: 407-413.

- Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. *Am J Clin Nutr* 1998; 68: 854-858.
- Grover SR, Morley R. Vitamin D deficiency in veiled or dark-skinned pregnant women. *Med J Aust* 2001; 175: 251-252.
- Nozza JM, Rodda CP. Vitamin D deficiency in mothers of infants with rickets. *Med J Aust* 2001; 175: 253-255.
- Hollis BW. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. *Clin Chem* 2000; 46: 1657-1661. □

Rebecca S Mason,* Terrence H Diamond†

* Associate Professor, Department of Physiology, University of Sydney, NSW 2006; † Senior Endocrinologist, Department of Endocrinology, St George Hospital, Kogarah, NSW.
rebeccam@physiol.usyd.edu.au

IN REPLY: Glendenning raises a number of interesting points, which require some clarification.

Are ergocalciferol (vitamin D₂) and cholecalciferol (vitamin D₃) biologically equivalent?

The statement that ergocalciferol and cholecalciferol are bioequivalent in humans is made by most authoritative textbooks, based mainly on evidence from early studies of the antirachitic efficacy of ergocalciferol and cholecalciferol compounds, and contrasts with reduced efficacy of ergocalciferol in birds and monkeys.¹ Recent studies using more precise measurements have raised some doubts as to the absolute equivalency of ergo- and cholecalciferol, but the differences are marginal² and not universally found.³ There are few recent data on relevant biological endpoints. Serum concentrations of the active hormone, 1,25-dihydroxyvitamin D, were not different after administration of ergo- or cholecalciferol,² and increases in bone mineral density were greater after ergocalciferol therapy than after cholecalciferol in patients taking anticonvulsants.¹ In short, on current evidence, differences in biological activity between ergocalciferol and cholecalciferol are likely to be relatively minor.

Are there problems monitoring therapy?

25-Hydroxyvitamin D values may be used for monitoring treatment. The possibilities of impaired detection of the 25-hydroxy metabolite of ergocalciferol by some assays,² and perhaps a smaller rise in total 25-hydroxyvitamin D concentrations after low doses of ergocalciferol, should be borne in mind when monitoring therapy.

What is the current recommendation for vitamin D supplementation?

While the availability of larger dose sizes and/or cholecalciferol preparations would be helpful, 800 IU of ergocalciferol and 1 g of calcium for six months was shown to reduce secondary hyperparathyroidism in older patients,¹ and 600 IU/day (same for

ergo- and cholecalciferol) is the new recommended adequate intake for older patients with limited sun exposure.¹

- Holick MF. Vitamin D: Photobiology, metabolism, mechanism of action, and clinical applications. In: Favus M, editor. *Primer on the metabolic bone diseases and disorders of mineral metabolism*. Philadelphia: Lippincott Williams & Wilkins, 1999: 92-98.
- Trang HM, Cole DEC, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. *Am J Clin Nutr* 1998; 68: 854-858.
- Gertner JM, Domenech M. 25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol. *Clin Path* 1977; 30: 144-150.
- Tjellessen L, Gotfredsen A, Christiansen C. Different actions of vitamin D2 and D3 on bone metabolism in patients treated with phenobarbitone/phenytoin. *Calcif Tissue Int* 1985; 37: 218-222.
- Chapuy MC, Chapuy P, Meunier PJ. Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. *Am J Clin Nutr* 1987; 46: 324-328. □

Confronting conflict of interest in research organisations: time for national action

Max Kamien

Professor, Department of General Practice, University of Western Australia, 328 Stirling Highway, Claremont, WA 6010. mkamien@cyllene.uwa.edu.au

TO THE EDITOR: A recent editorial in the *Journal* focused on the "blurring of research ideals and corporate interests".¹ But there are other funding and commissioning bodies, including government, whose wants or needs also have the potential to blur research ideals and exert control over what can be published. In recent times, those who pay the piper increasingly want to call the tune. Understandably, this is also an issue for research into Aboriginal ill health.^{2,3} Van Der Weyden's plea for the development of national guidelines on institutional conflict of interest should therefore be broadened to include all funding bodies.

One suggestion for inclusion in these guidelines, to enhance public interest in research, is an obligation for authors to state not only their sources of funding, but "the origin of the research question they are attempting to answer"⁴ and the person or group who initiated the funding of the project.

- Van Der Weyden MB. Confronting conflict of interest in research organisations: time for national action [editorial]. *Med J Aust* 2001; 175: 396-397.
- Eades SJ, Read AW, and the Bibbulung Gnarneep Team. The Bibbulung Gnarneep Project: practical implementation of guidelines on ethics in Indigenous health research. *Med J Aust* 1999; 170: 433-436.
- Kamien M. The Bibbulung Gnarneep Project: practical implementation of guidelines on ethics in Indigenous health research [letter]. *Med J Aust* 1999; 171: 389-390.
- O'Dowd T. Research in general practice: who is calling the tune? [editorial] *Br J Gen Pract* 1995; 45: 515. □

Recent appearance of clindamycin resistance in community-acquired methicillin-resistant *Staphylococcus aureus* (MRSA) in south-east Queensland

Wendy J Munckhof,* Jacqueline Harper,†
Jacqueline Schooneveld,‡
Graeme R Nimmo[§]

* Specialist in Infectious Diseases and Microbiology, Ipswich Hospital, and Specialist in Infectious Diseases (corresponding author); † Chief Scientist; ‡ Scientist; § Director, Microbiology Department, Queensland Health Pathology Service, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, QLD 4102. wendy_munckhof@health.qld.gov.au

TO THE EDITOR: We report the appearance of erythromycin and inducible clindamycin resistance in the south-west Pacific strain of non-multiresistant methicillin-resistant *Staphylococcus aureus*, which has recently appeared in eastern Australia. Infections occur predominantly in Polynesian people and are usually community-acquired. Most strains belong to Western Samoan phage patterns (WSPP1 or WSPP2) and pulso-type A when typed by pulsed-field gel electrophoresis.^{1,2} These strains are resistant to all β -lactams, but are usually susceptible to erythromycin, clindamycin, gentamicin, tetracycline, trimethoprim-sulfamethoxazole and ciprofloxacin. Although most of these antibiotics would not be recommended for therapy,³ clindamycin has been recommended for non-parenteral treatment of soft-tissue and bone infections, as it is efficacious in treating similar infections caused by methicillin-susceptible *S. aureus*.⁴

Twenty isolates of community-acquired, non-multiresistant pulso-type A MRSA were collected from patients from southern Brisbane and Logan in 1997 and 1998.² A further 16 isolates were obtained from Ipswich patients between December 1998 and February 2001. We found that all 36



Save Time

Articles submitted in correct MJA format will have a speedier journey to publication!

MJA Advice to Authors on the Internet:
www.mja.com.au/public/information/instruc.html

Alternatively, phone (02) 9562 6666 to receive a facsimile copy